Tucatinib and Trastuzumab for Rectal Cancer

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Recruiting Phase 2 Interventional Study
Adenocarcinoma of the Rectum Locally Advanced Rectal Adenocarcinoma Rectal Adenocarcinoma HER2 Positive Rectal Adenocarcinoma Rectal Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
37 (estimated)
Sponsor
Memorial Sloan Kettering Cancer Center · Other
Who this trial is looking for

This trial is looking for people with rectal cancer, specifically those with certain cancer characteristics. Participants will receive a combination of two drugs along with standard chemotherapy to see if it helps their condition.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am at least 18 years old.
  • I have been diagnosed with rectal adenocarcinoma.
  • I have confirmed HER2-positive rectal adenocarcinoma.
  • I have no distant metastases.
  • I am willing to use contraception if I can get pregnant.
  • I have adequate organ function.
  • I can provide written consent.

You may not be able to join if

  • I have recurrent rectal cancer.
  • I have had previous treatment for rectal cancer.
  • I have a tumor causing a bowel obstruction.
  • I have another cancer within the last 5 years.
  • I have an active infection that needs treatment.
  • I have a history of HIV.
  • I am currently pregnant or breastfeeding.
  • I have a chronic liver disease.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX), may help participants with rectal cancer.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Willing and able to provide written informed consent for the trial. * Be ≥18 years of age on the date of signing informed consent. * ECOG performance status of 0 or 1. * Histologically confirmed rectal adenocarcinoma. * Adenocarcinoma with distal margin of 15 cm or less from t…
Contacts

Andrea Cercek, MD

646-888-4189

cerceka@mskcc.org

CONTACT

Rona Yaeger, MD

646-888-5109

yaegerr@mskcc.org

CONTACT